Screening
What preventive health screening actually catches — and what it misses
8 min read
Most people meet preventive screening as a package: a clinic offers a panel, you pay, you get a printout. The printout rarely explains which of those tests has evidence behind it, which is there because it is cheap to run, and which is likely to send you down an expensive path for nothing.
The distinction matters. A screening test only helps if finding the condition early changes what happens to you. That is a higher bar than 'the test can detect something', and most tests do not clear it.
The tests with the strongest evidence
A short list of screening programmes has repeatedly shown that early detection reduces death or serious disease. These are the ones worth organising your calendar around.
- Blood pressure measurement — cheap, immediate, and hypertension is silent until it is not
- Colorectal cancer screening from age 45, by colonoscopy or stool-based testing
- Cervical screening with HPV testing, which has transformed cervical cancer incidence
- Mammography from age 40–50 depending on the guideline body and personal risk
- Low-dose CT for lung cancer in people with a substantial smoking history
- HbA1c or fasting glucose for type 2 diabetes, where the prediabetes window is genuinely reversible
- Lipid profile, because the treatment decision depends on absolute risk, not the number alone
Where screening quietly fails
Two failure modes dominate. The first is overdiagnosis: finding something real that would never have harmed you, then treating it anyway. Thyroid cancer screening is the textbook case — detection rates rose many-fold in countries that screened, while deaths did not move.
The second is the false positive cascade. A borderline tumour marker leads to a scan, the scan finds an incidental nodule, the nodule leads to a biopsy. Each step carries cost, risk and anxiety, and the chain often ends where it started.
This is why whole-body scans and broad tumour-marker panels in people without symptoms are not recommended by any major guideline body, however reassuring the marketing sounds.
Risk stratification beats more testing
The single highest-yield move is usually not another test. It is taking the values you already have — blood pressure, cholesterol, HbA1c, age, smoking status, family history — and running them through a validated risk model.
A 10-year cardiovascular risk of 4% and one of 18% call for completely different conversations, even when the individual numbers look similar. The model is what turns a list of results into a decision.
Building a screening plan you will actually follow
Start with age and sex-based guideline screening, add anything your family history justifies, and set the recall dates. Then stop. Adding tests beyond that rarely improves outcomes and reliably increases false alarms.
- Write down every screening test you are due, with the date it is next due
- Record family history properly — which relative, which condition, at what age
- Repeat the modifiable measures (blood pressure, HbA1c, lipids) on a fixed interval
- Track the trend, not the single reading
Key takeaways
- A screening test is only worth doing if early detection changes the outcome.
- Overdiagnosis and false-positive cascades are the main harms, and they are not rare.
- Running your existing numbers through a validated risk model usually beats ordering more tests.
- Guideline-based screening plus a documented family history covers the overwhelming majority of real benefit.
Related reading
Sources
- US Preventive Services Task Force, A and B Recommendations
- American Cancer Society, Guidelines for the Early Detection of Cancer
- Welch HG, Black WC. Overdiagnosis in cancer, JNCI 2010
This article is educational and is not medical advice. Always discuss your own results with a qualified healthcare professional.
Know your risk, take action
Create a free account and get your first risk assessment in under ten minutes. No card required.